Buyer· Panama· Activity through Sep 2026

Centro Regional de Innovación en Vacunas y Biofármacos AIP

3554

In 2026 in PanamaCompra procurement indicators, Centro Regional de Innovación en Vacunas y Biofármacos AIP appears as a buyer in 7 records from PanamaCompra procurement indicators, which amount to 7 unique processes. The observed amount totals 10,631 PAB. The leading supplier by amount, Magna Tours, accounts for 56.7% of the PAB amount.

Create and download this entity’s chart
Source records
7
Sources
1

Observed volume

7 processes

7 source rows in PanamaCompra procurement indicators.

Latest activity

Sep 2026

4 records in the period.

Leading supplier by amount

Magna Tours

56.7% of observed PAB amount; top three 96.8%.

History

Historical series by source

2 independent series

Relationships

Top counterparties in the records

Ranked by shared record count, without adding different currencies.

Relationship concentration

Reliance on leading suppliers

Each currency is calculated separately. A high share may reflect specialization, scale, or source coverage and is not by itself evidence of misconduct.

Magna ToursAmount · PABTop one 56.7%Top three 96.8%
C Viaja, S.A.Recorded relationshipsTop one 28.6%Top three 57.1%

Recent activity

Latest published records

Ordered by the most relevant award, publication, or event date in each source. An identical event published by multiple lifecycle sources is shown once and retains every source in the first column. This does not claim the activity happened today.

The summary is available, but a recent record sample could not be loaded. Consult the records in the cited sources.

Entity monitoring

Monitor Centro Regional de Innovación en Vacunas y Biofármacos AIP

Get an email when linked records change. Alerts make clear that a change may be new activity, broader coverage, or a source correction.

Coverage and provenance

Sources contributing to this profile

This profile consolidates source keys within one country and role only through exact identifiers or an unambiguous normalized legal name. Currencies and unit scales remain separate; similar names are not assumed to be the same organization.